Metagenomi Therapeutics (MGX)
Develops genetic medicines from microbial genome-editing systems.
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.54 per share a year ago.
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK,
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus PT from Analysts
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Metagenomi (MGX) to Release Earnings on Wednesday
Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus Target Price from Analysts
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.63 per share a year ago.
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the full year ended December 31, 2025, and provided business updates.
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript
MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript
Hiab expands US footprint with appointment of MGX Equipment Services as new dealer in 13 states
HIAB CORPORATION, PRESS RELEASE, 9 FEBRUARY 2026 AT 3:00 PM (EET) Hiab expands US footprint with appointment of MGX Equipment Services as new dealer in 13 states Hiab, a leading provider of smart and sustainable on-road load handling solutions, has signed a strategic dealer agreement with MGX Equipment Services LLC (MGX) expanding the distribution and service network for HIAB loader cranes across 13 states in the US. MGX is a wholly-owned subsidiary of The Manitowoc Company, Inc. (NYSE: MTW).
Metagenomi (NASDAQ:MGX) Shares Down 1.2% – Here’s Why
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) shares dropped 1.2% during trading on Monday. The stock traded as low as $1.64 and last traded at $1.67. Approximately 197,840 shares were traded during trading, a decline of 29% from the average daily volume of 280,509 shares. The stock had previously closed at $1.69. Analyst Ratings
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has completed its corporate name change to Metagenomi Therapeutics, Inc. to reflect the Company's strategic evolution focused on driving forward the Company's lead program in hemophilia A and other compelling programs and technologies that have the highest probability of near-term success.
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating